Predicting cognitive decline in Alzheimer's disease: an integrated analysis

TY - JOUR

T1 - Predicting cognitive decline in Alzheimer's disease: an integrated analysis

AU - Lopez, Oscar L

AU - Schwam, Elias

AU - Cummings, Jeffrey

AU - Gauthier, Serge

AU - Jones, Roy

AU - Wilkinson, David

AU - Waldemar, Gunhild

AU - Zhang, Richard

AU - Schindler, Rachel

N1 - Copyright © 2010 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Background: Numerous patient- and disease-related factors increase the risk of rapid cognitive decline in patients with Alzheimer's disease (AD). The ability of pharmacological treatment to attenuate this risk remains undefined. Methods: Pooled data from 14 randomized clinical studies of donepezil in the treatment of AD (N = 3748) were analyzed to identify predictors of fast decline and determine the effect of donepezil on the risk of fast decline. Results: Young age and more severe baseline cognitive, global, or behavioral status were identified as independent predictors of faster decline in placebo-treated patients. Multivariate models indicated that donepezil treatment was associated with a 39% to 63% reduction in the risk of faster decline. Conclusions: These results correspond with previous findings, indicating relationships between age or baseline disease severity and rates of cognitive decline. Furthermore, they suggest that symptomatic therapy for AD could reduce the likelihood of faster decline in treated patients.

AB - Background: Numerous patient- and disease-related factors increase the risk of rapid cognitive decline in patients with Alzheimer's disease (AD). The ability of pharmacological treatment to attenuate this risk remains undefined. Methods: Pooled data from 14 randomized clinical studies of donepezil in the treatment of AD (N = 3748) were analyzed to identify predictors of fast decline and determine the effect of donepezil on the risk of fast decline. Results: Young age and more severe baseline cognitive, global, or behavioral status were identified as independent predictors of faster decline in placebo-treated patients. Multivariate models indicated that donepezil treatment was associated with a 39% to 63% reduction in the risk of faster decline. Conclusions: These results correspond with previous findings, indicating relationships between age or baseline disease severity and rates of cognitive decline. Furthermore, they suggest that symptomatic therapy for AD could reduce the likelihood of faster decline in treated patients.

U2 - 10.1016/j.jalz.2010.04.003

DO - 10.1016/j.jalz.2010.04.003

M3 - Journal article

SN - 1552-5260

VL - 6

SP - 431

EP - 439

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

IS - 6

ER -